ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022
Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 23 citations in OpenAlex.
- Special Issue "Molecular Advances in Biomarkers of Central Nervous System Diseases and Disorders".International journal of molecular sciences · 2026Article
- Addressing nonignorable missing data and heterogeneity in prognostic biomarker assessment.Statistical methods in medical research · 2026Article
- Alterations in CSF Amyloid-β and Tau Biomarkers in Former College and Professional American Football Players: Findings from the DIAGNOSE CTE Research Project.Journal of neurotrauma · 2026Observational
- Association Between Longitudinal Rate of Change in CSF Biomarkers and Subsequent Tau PET Burden in Early Braak Stages.Neurology · 2026Article
- Rising energetic cost of walking predicts cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Article
- CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals.Annals of clinical and translational neurology · 2026Article
- Modeling the age-specific incidence of mild cognitive impairment incorporating the time-varying relationship of Alzheimer's disease biomarkers over 28 years.Journal of Alzheimer's disease : JAD · 2026Article
- Tau burden across Braak stages is associated with regionally specific amyloid accumulation.Brain communications · 2026Article
- Cognitive resilience in preclinical Alzheimer's disease: Higher NPTX2 and VGF levels are associated with reduced cognitive decline.Neurobiology of aging · 2025Article
- Cerebellar White Matter Microstructure Is Associated With Age, Cerebrospinal Fluid Amyloid Beta Levels, and Cognition in Cognitively Unimpaired Older Adults.Human brain mapping · 2025Article
- Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum.JAMA network open · 2025Article
- Effects of Diminished Cerebrospinal Fluid Flow in the Spinal Canal on Amyloid Pathophysiology in Vervet Monkeys.Research square · 2025Article
- Analyzing heterogeneity in biomarker discriminative performance through partial time-dependent receiver operating characteristic curve modeling.Statistical methods in medical research · 2024Article
- A Bayesian semi-parametric model for learning biomarker trajectories and changepoints in the preclinical phase of Alzheimer's disease.Biometrics · 2024Article
- Inferring Alzheimer's disease pathologic traits from clinical measures in living adults.medRxiv : the preprint server for health sciences · 2024Article
- Inferring Alzheimer's Disease Pathologic Traits from Clinical Measures in Living Adults.Journal of Alzheimer's disease : JAD · 2024Article
- NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment.Annals of neurology · 2023Article
- Cerebrospinal Fluid Alzheimer's Disease Biomarker Patterns of Change Prior to the Onset of Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2023Article
- Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Introduction: We examined longitudinal cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarker changes among cognitively normal individuals with 10.7 years follow-up, on average. Methods: Analyses included 278 participants ( Results: Apolipoprotein E ( Discussion: Our results confirm accelerated biomarker changes during preclinical AD and highlight the important role of amyloid levels in tau accelerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.